Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide

Datamonitor's Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, China) Pharmaceuticals industry. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights

Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the pharmaceuticals industry and had a total market value of $63.7 Billion in 2010. China was the fastest growing country with a CAGR of 17.2% over the 2006–10 period.

China is the leading country among the BRIC nations with market revenues of $25.7 Billion in 2010.

China is expected to lead the pharmaceuticals industry in the BRIC nations with a value of $48.8, Billion in 2015

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2009 annual average exchange rates.
[Studien Infos ausblenden]

TABLE OF CONTENTS
INTRODUCTION 11
What is this report about? 11
Who is the target reader? 11
Market definition 11
BRIC PHARMACEUTICALS INDUSTRY OUTLOOK 12
PHARMACEUTICALS IN BRAZIL 18
Market overview 18
Market value 19
Market segmentation I 20
Market segmentation II 21
Market share 22
Five forces analysis 23
Leading companies 32
Market forecasts 46
Macroeconomic indicators 48
PHARMACEUTICALS IN RUSSIA 50
Market overview 50
Market value 51
Market segmentation I 52
Market segmentation II 54
Market share 55
Five forces analysis 56
Leading companies 63
Market forecasts 74
Macroeconomic indicators 76
PHARMACEUTICALS IN INDIA 78
Market overview 78
Market value 79
Market segmentation I 80
Market segmentation II 82
Market share 83
Five forces analysis 84
Leading companies 93
Market forecasts 114
Macroeconomic indicators 116
PHARMACEUTICALS IN CHINA 118
Market overview 118
Market value 119
Market segmentation I 120
Market segmentation II 121
Market share 122
Five forces analysis 123
Leading companies 132
Market forecasts 151
Macroeconomic indicators 153
APPENDIX 155
Data Research Methodology 155
About Datamonitor 156
Disclaimer 156

LIST OF TABLES
Table 1: BRIC pharmaceuticals industry, revenue($bn), 2006–15 13
Table 2: BRIC pharmaceuticals industry, revenue($bn), 2006–10(e) 15
Table 3: BRIC pharmaceuticals industry, revenue($bn), 2010–15 17
Table 4: Brazil pharmaceuticals market value: $ billion, 2006–10(e) 19
Table 5: Brazil pharmaceuticals market segmentation I:% share, by value, 2010(e) 20
Table 6: Brazil pharmaceuticals market segmentation II: % share, by value, 2010(e) 21
Table 7: Brazil pharmaceuticals market share: % share, by value, 2010(e) 22
Table 8: Aché Laboratórios Farmacêuticos S.A.: key facts 32
Table 9: EMS Sigma Pharma : key facts 34
Table 10: GlaxoSmithKline Plc: key facts 35
Table 11: GlaxoSmithKline Plc: key financials ($) 37
Table 12: GlaxoSmithKline Plc: key financials (£) 38
Table 13: GlaxoSmithKline Plc: key financial ratios 38
Table 14: Novartis AG: key facts 41
Table 15: Novartis AG: key financials ($) 43
Table 16: Novartis AG: key financial ratios 43
Table 17: Brazil pharmaceuticals market value forecast: $ billion, 2010–15 46
Table 18: Brazil size of population (million), 2006–10 48
Table 19: Brazil GDP (constant 2000 prices, $ billion), 2006–10 48
Table 20: Brazil GDP (current prices, $ billion), 2006–10 48
Table 21: Brazil inflation, 2006–10 49
Table 22: Brazil consumer price index (absolute), 2006–10 49
Table 23: Brazil exchange rate, 2006–10 49
Table 24: Russia pharmaceuticals market value: $ billion, 2006–10(e) 51
Table 25: Russia pharmaceuticals market segmentation I:% share, by value, 2010(e) 52
Table 26: Russia pharmaceuticals market segmentation II: % share, by value, 2010(e) 54
Table 27: Russia pharmaceuticals market share: % share, by value, 2010(e) 55
Table 28: Novartis AG: key facts 63
Table 29: Novartis AG: key financials ($) 65
Table 30: Novartis AG: key financial ratios 65
Table 31: Pharmstandard: key facts 68
Table 32: Sanofi-Aventis SA: key facts 69
Table 33: Sanofi-Aventis SA: key financials ($) 71
Table 34: Sanofi-Aventis SA: key financials (€) 71
Table 35: Sanofi-Aventis SA: key financial ratios 71
Table 36: Russia pharmaceuticals market value forecast: $ billion, 2010–15 74
Table 37: Russia size of population (million), 2006–10 76
Table 38: Russia GDP (constant 2000 prices, $ billion), 2006–10 76
Table 39: Russia GDP (current prices, $ billion), 2006–10 76
Table 40: Russia inflation, 2006–10 77
Table 41: Russia consumer price index (absolute), 2006–10 77
Table 42: Russia exchange rate, 2006–10 77
Table 43: India pharmaceuticals market value: $ billion, 2006–10(e) 79
Table 44: India pharmaceuticals market segmentation I:% share, by value, 2010(e) 80
Table 45: India pharmaceuticals market segmentation II: % share, by value, 2010(e) 82
Table 46: India pharmaceuticals market share: % share, by value, 2010(e) 83
Table 47: Cipla Ltd: key facts 93
Table 48: Cipla Ltd: key financials ($) 96
Table 49: Cipla Ltd: key financials (Rs.) 96
Table 50: Cipla Ltd: key financial ratios 97
Table 51: GlaxoSmithKline Plc: key facts 99
Table 52: GlaxoSmithKline Plc: key financials ($) 102
Table 53: GlaxoSmithKline Plc: key financials (£) 102
Table 54: GlaxoSmithKline Plc: key financial ratios 102
Table 55: Piramal Healthcare Limited: key facts 105
Table 56: Piramal Healthcare Limited: key financials ($) 107
Table 57: Piramal Healthcare Limited: key financials (Rs.) 107
Table 58: Piramal Healthcare Limited: key financial ratios 107
Table 59: Ranbaxy Laboratories Limited: key facts 110
Table 60: Ranbaxy Laboratories Limited: key financials ($) 111
Table 61: Ranbaxy Laboratories Limited: key financials (Rs.) 111
Table 62: Ranbaxy Laboratories Limited: key financial ratios 112
Table 63: India pharmaceuticals market value forecast: $ billion, 2010–15 114
Table 64: India size of population (million), 2006–10 116
Table 65: India GDP (constant 2000 prices, $ billion), 2006–10 116
Table 66: India GDP (current prices, $ billion), 2006–10 116
Table 67: India inflation, 2006–10 117
Table 68: India consumer price index (absolute), 2006–10 117
Table 69: India exchange rate, 2006–10 117
Table 70: China pharmaceuticals market value: $ billion, 2006–10(e) 119
Table 71: China pharmaceuticals market segmentation I:% share, by value, 2010(e) 120
Table 72: China pharmaceuticals market segmentation II: % share, by value, 2010(e) 121
Table 73: China pharmaceuticals market share: % share, by value, 2010(e) 122
Table 74: AstraZeneca PLC: key facts 132
Table 75: AstraZeneca PLC: key financials ($) 134
Table 76: AstraZeneca PLC: key financial ratios 135
Table 77: GlaxoSmithKline Plc: key facts 137
Table 78: GlaxoSmithKline Plc: key financials ($) 139
Table 79: GlaxoSmithKline Plc: key financials (£) 140
Table 80: GlaxoSmithKline Plc: key financial ratios 140
Table 81: Northeast Pharmaceutical Group Company Limited: key facts 143
Table 82: Pfizer Inc.: key facts 144
Table 83: Pfizer Inc.: key financials ($) 146
Table 84: Pfizer Inc.: key financial ratios 146
Table 85: Yangtze River Pharmaceutical Group: key facts 149
Table 86: China pharmaceuticals market value forecast: $ billion, 2010–15 151
Table 87: China size of population (million), 2006–10 153
Table 88: China GDP (constant 2000 prices, $ billion), 2006–10 153
Table 89: China GDP (current prices, $ billion), 2006–10 153
Table 90: China inflation, 2006–10 154
Table 91: China consumer price index (absolute), 2006–10 154
Table 92: China exchange rate, 2006–10 154

LIST OF FIGURES
Figure 1: BRIC pharmaceuticals industry, revenue($bn), 2006–15 12
Figure 2: BRIC pharmaceuticals industry, revenue($bn), 2006–10(e) 14
Figure 3: BRIC pharmaceuticals industry, revenue($bn), 2010–15 16
Figure 4: Brazil pharmaceuticals market value: $ billion, 2006–10(e) 19
Figure 5: Brazil pharmaceuticals market segmentation I:% share, by value, 2010(e) 20
Figure 6: Brazil pharmaceuticals market segmentation II: % share, by value, 2010(e) 21
Figure 7: Brazil pharmaceuticals market share: % share, by value, 2010(e) 22
Figure 8: Forces driving competition in the pharmaceuticals market in Brazil, 2010 23
Figure 9: Drivers of buyer power in the pharmaceuticals market in Brazil, 2010 25
Figure 10: Drivers of supplier power in the pharmaceuticals market in Brazil, 2010 26
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Brazil, 2010 28
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Brazil, 2010 30
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Brazil, 2010 31
Figure 14: GlaxoSmithKline Plc: revenues & profitability 39
Figure 15: GlaxoSmithKline Plc: assets & liabilities 40
Figure 16: Novartis AG: revenues & profitability 44
Figure 17: Novartis AG: assets & liabilities 45
Figure 18: Brazil pharmaceuticals market value forecast: $ billion, 2010–15 47
Figure 19: Russia pharmaceuticals market value: $ billion, 2006–10(e) 51
Figure 20: Russia pharmaceuticals market segmentation I:% share, by value, 2010(e) 53
Figure 21: Russia pharmaceuticals market segmentation II: % share, by value, 2010(e) 54
Figure 22: Russia pharmaceuticals market share: % share, by value, 2010(e) 55
Figure 23: Forces driving competition in the pharmaceuticals market in Russia, 2010 56
Figure 24: Drivers of buyer power in the pharmaceuticals market in Russia, 2010 57
Figure 25: Drivers of supplier power in the pharmaceuticals market in Russia, 2010 58
Figure 26: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2010 59
Figure 27: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2010 61
Figure 28: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2010 62
Figure 29: Novartis AG: revenues & profitability 66
Figure 30: Novartis AG: assets & liabilities 67
Figure 31: Sanofi-Aventis SA: revenues & profitability 72
Figure 32: Sanofi-Aventis SA: assets & liabilities 73
Figure 33: Russia pharmaceuticals market value forecast: $ billion, 2010–15 75
Figure 34: India pharmaceuticals market value: $ billion, 2006–10(e) 79
Figure 35: India pharmaceuticals market segmentation I:% share, by value, 2010(e) 81
Figure 36: India pharmaceuticals market segmentation II: % share, by value, 2010(e) 82
Figure 37: India pharmaceuticals market share: % share, by value, 2010(e) 83
Figure 38: Forces driving competition in the pharmaceuticals market in India, 2010 84
Figure 39: Drivers of buyer power in the pharmaceuticals market in India, 2010 85
Figure 40: Drivers of supplier power in the pharmaceuticals market in India, 2010 87
Figure 41: Factors influencing the likelihood of new entrants in the pharmaceuticals market in India, 2010 89
Figure 42: Factors influencing the threat of substitutes in the pharmaceuticals market in India, 2010 90
Figure 43: Drivers of degree of rivalry in the pharmaceuticals market in India, 2010 91
Figure 44: Cipla Ltd: revenues & profitability 97
Figure 45: Cipla Ltd: assets & liabilities 98
Figure 46: GlaxoSmithKline Plc: revenues & profitability 103
Figure 47: GlaxoSmithKline Plc: assets & liabilities 104
Figure 48: Piramal Healthcare Limited: revenues & profitability 108
Figure 49: Piramal Healthcare Limited: assets & liabilities 109
Figure 50: Ranbaxy Laboratories Limited: revenues & profitability 112
Figure 51: Ranbaxy Laboratories Limited: assets & liabilities 113
Figure 52: India pharmaceuticals market value forecast: $ billion, 2010–15 115
Figure 53: China pharmaceuticals market value: $ billion, 2006–10(e) 119
Figure 54: China pharmaceuticals market segmentation I:% share, by value, 2010(e) 120
Figure 55: China pharmaceuticals market segmentation II: % share, by value, 2010(e) 121
Figure 56: China pharmaceuticals market share: % share, by value, 2010(e) 122
Figure 57: Forces driving competition in the pharmaceuticals market in China, 2010 123
Figure 58: Drivers of buyer power in the pharmaceuticals market in China, 2010 124
Figure 59: Drivers of supplier power in the pharmaceuticals market in China, 2010 125
Figure 60: Factors influencing the likelihood of new entrants in the pharmaceuticals market in China, 2010 127
Figure 61: Factors influencing the threat of substitutes in the pharmaceuticals market in China, 2010 129
Figure 62: Drivers of degree of rivalry in the pharmaceuticals market in China, 2010 131
Figure 63: AstraZeneca PLC: revenues & profitability 135
Figure 64: AstraZeneca PLC: assets & liabilities 136
Figure 65: GlaxoSmithKline Plc: revenues & profitability 141
Figure 66: GlaxoSmithKline Plc: assets & liabilities 142
Figure 67: Pfizer Inc.: revenues & profitability 147
Figure 68: Pfizer Inc.: assets & liabilities 148
Figure 69: China pharmaceuticals market value forecast: $ billion, 2010–15 152



[Inhaltsverzeichnis ausblenden]